Roth Capital initiated coverage on Clene with a new price target
$CLNN
Biotechnology: Pharmaceutical Preparations
Health Care
Roth Capital initiated coverage of Clene with a rating of Buy and set a new price target of $24.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/4/2022 | Outperform → Perform | Oppenheimer | |
| 7/18/2022 | $16.00 | Buy | H.C. Wainwright |
| 5/2/2022 | $10.00 | Buy | Canaccord Genuity |
| 9/28/2021 | $20.00 | Outperform | Oppenheimer |